Display

Steven Zullo, Ph.D.
Division of Basic and Integrative Biological Sciences

Scientific Review Officer
Bioengineering Sciences and Technologies (BST)
Biomaterials and Biointerfaces (BMBI)

NIH/CSR
Center for Scientific Review, Room 5146
6701 Rockledge Dr. Bethesda, MD 20892

Email: zullost@csr.nih.gov

Phone Number: 301-435-2810

Dr. Steve Zullo is the Scientific Review Officer for the Gene and Drug Delivery Systems study section of the Bioengineering Sciences and Technologies Integrated Review Group. After a postdoctoral fellowship at Yale School of Medicine, Dr. Zullo joined the Laboratory of Biochemical Genetics at National Institute of Mental Health in 1991, where he created the first mammalian (Chinese Hamster Ovary) cell line with a functional mitochondrial DNA-encoded gene stably integrated into the nuclear genome (termed allotopic expression). Dr. Zullo assembled an intramural/extramural team that first demonstrated protease inhibitors (PIs)designed to block the HIV protease that could also block the mitochondrial processing protease. This mechanism might contribute to the lipodystrophy syndromes that first surfaced when PIs were combined with nucleoside analogues in highly active antiretroviral therapy. Dr. Zullo also spearheaded the institution of the NIH Mitochondria Interest Group officially in 1997. Dr. Zullo managed chemistry and life sciences projects for the Advanced Technology Program of the National Institute of Standards and Technology from the end of 2000 until early 2004, when he returned to the NIH.